Archives

  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • Nienhuijs SW et al Nationwide improvement

    2020-08-12

    [21] Nienhuijs SW, et al. Nationwide improvement of only short-term survival after resection for pancreatic cancer in The Netherlands. Pancreas 2012;41: 1063e6.
    [23] Rouvelas I, et al. Survival after surgery for oesophageal cancer: a population-based study. Lancet Oncol 2005;6:864e70. [24] Ludvigsson JF, et al. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 2009;24:659e67. [25] Socialstyrelsen. Kodning i cancerregistret 2017: arbetsdokument for€ personal
    [26] Sobin MG LH, Wittekind C, editors. TNM classification of malignant tumours. City: Wiley-Blackwell; 2009. [27] Barlow L, et al. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 2009;48:27e33. [28] Brusselaers N, et al. Tumour staging of oesophageal cancer in the Swedish Cancer Registry: a nationwide validation study. Acta Oncol 2015;54:903e8. [29] Socialstyrelsen. Klassifikation av kirurgiska åtgarder€ 1997 [Internet]. In: City:
    [30] Armitage JN, et al. Identifying co-morbidity in surgical patients using administrative data with the Royal College of Surgeons Charlson Score. Br J Surg 2010;97:772e81.
    [31] Brusselaers N, Lagergren J. The Charlson comorbidity Index in registry-based research. Methods Inf Med 2017;56:401e6. [32] Lagergren K, Derogar M. Validation of oesophageal cancer surgery data in the Swedish Patient Registry. Acta Oncol 2012;51:65e8. [33] Ludvigsson JF, et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011;11:450. [34] Socialstyrelsen. Dodsorsaker€ 2014: causes of death 2014 [internet]. In: City:
    from: http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/19909/ 2015-8-1.pdf. [35] Little RJA RD. Statistical analysis with missing data. second ed. Hoboken, N.J.: Wiley; 2002. [36] Huo YR, et al. Systematic review and a meta-analysis of hospital and surgeon volume/outcome relationships in colorectal cancer surgery. J Gastrointest Oncol 2017;8:534e46.
    [37] Brusselaers N, et al. Hospital and surgeon volume in relation to long-term survival after oesophagectomy: systematic review and meta-analysis. Gut 2014;63:1393e400.
    [38] Gooiker GA, et al. Systematic review and meta-analysis of the volume-outcome relationship in pancreatic surgery. Br J Surg 2011;98:485e94. [39] Fong Y, et al. Long-term survival is superior after resection for cancer in high-volume centers. Ann Surg 2005;242:540e4. discussion 4-7. [40] Ioka A, et al. Hospital procedure volume and survival of cancer patients in Osaka, Japan: a population-based study with latest cases. Jpn J Clin Oncol 2007;37:544e53.
    [41] Buurma M, et al. Influence of individual surgeon volume on oncological outcome of colorectal cancer surgery. Int J Surg Oncol 2015;2015:464570.
    Please cite this 61036-62-2 article as: Gottlieb-Vedi E et al., Annual hospital volume of surgery for gastrointestinal cancer in relation to prognosis, European Journal of Surgical Oncology, https://doi.org/10.1016/j.ejso.2019.03.016 
    Journal of Natural
    Medicines
    •Special topic•
    Anti-cancer activities of S-allylmercaptocysteine
    from aged garlic
    1 Laboratory of Neuroendocrinology, School of Biological Sciences, Fujian Normal University, Fuzhou 350117, China;
    2 National Key Disciplines for Infectious Diseases, Shenzhen Third People’s Hospital, The Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen 518112, China;
    3 School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong 999077, China
    [ABSTRACT] While most types of malignancies remain recalcitrant to treatment, application of natural products or their analogs in daily life has offered some hopes as an effective prophylaxis against cancer onset and progression in the past decades. Emerging evidence supports a link between garlic consumption and decreased cancer incidence. Notably, aged garlic extract (AGE) exhibits stronger anti-cancer activities than that of fresh garlic, by virtue of enrichment of several AGE-specific organosulfur compounds, including S-allylmercaptocysteine (SAMC). In this review, we summarize the up-to-date mechanistic pathways associated with the anti-proliferative, anti-metastatic and pro-apoptotic effects of SAMC in various cancer models. Based upon the proven safety and improved understanding on its anti-neoplastic properties, SAMC has gained recognition as a promising daily food supplement for cancer prevention or management.
    [KEY WORDS] Aged garlic; S-allylmercaptocysteine; Cancer; Molecular pathway; Reactive oxygen species
    Introduction
    Allium sativum, commonly known as garlic, is a bulbous plant of the onion genus (Allium). It has a long history of being utilized as a foodstuff and an effective medicinal substance for centuries in countries such as Egypt and China [1-2]. Like other members of Allium, garlic has been valued for its broad effects in helping maintain the human body’s metabolic balance against vulnerability. Indeed, extensive experimental evidence from cell and animal models indicates that several garlic-derived organosulfur compounds are efficacious in reducing blood pressure, hyperlipidemia, and oxidative stress, while promoting cardiovascular and hepatic functions, prostanoids synthesis, and immune-regulation [3-4]. Recent epidemiological studies also demonstrate that garlic consumption is negatively associated with incidence of various cancer types, including stomach, colorectal, lung, prostate, and skin cancers [5-7].